

OMNICELL, Inc
Form 10-Q
November 09, 2007

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

FORM 10-Q

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2007

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**

For the transition period from _____ to _____

Commission File Number 0-33043

Omnicell, Inc.

(Exact name of registrant as specified in its charter)

Edgar Filing: OMNICELL, Inc - Form 10-Q

Delaware
(State or other jurisdiction
of incorporation or organization)

94-3166458
(I.R.S. Employer
Identification No.)

1201 Charleston Road

Mountain View, CA 94043

(650) 251-6100

(Address, including zip code, of registrant's principal executive
offices and registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class
Common Stock, \$0.001 par value

Outstanding as of November 6, 2007
34,484,534 shares

OMNICELL, INC.

FORM 10-Q

Table of Contents

	Page number
<u>PART I FINANCIAL INFORMATION</u>	
<u>Item 1.</u>	2
	2
	2
	3
	4
	5
<u>Item 2.</u>	14
<u>Item 3.</u>	21
<u>Item 4.</u>	22
<u>PART II OTHER INFORMATION</u>	22
<u>Item 1.</u>	22
<u>Item 1A.</u>	22
<u>Item 2.</u>	32
<u>Item 3.</u>	32
<u>Item 4.</u>	32
<u>Item 5.</u>	32
<u>Item 6.</u>	32
<u>SIGNATURES</u>	33
<u>INDEX TO EXHIBITS</u>	34

PART 1 FINANCIAL INFORMATION

Item 1. Financial Statements

OMNICELL, INC.

CONDENSED CONSOLIDATED BALANCE SHEET

(In thousands)

	September 30, 2007 (unaudited)		December, 31 2006 (1)
ASSETS			
Current Assets:			
Cash and cash equivalents	\$ 175,748	\$	60,856
Accounts receivable, net	46,927		34,021
Inventories	12,665		15,724
Prepaid expenses	9,273		8,033
Current deferred tax asset	7,973		
Other current assets	5,782		9,183
Total current assets	258,368		127,817
Property and equipment, net	7,945		5,226
Non-current net investment in sales-type leases	11,257		12,244
Non-current deferred tax asset	4,810		
Other assets	12,534		9,343
Total Assets	\$ 294,914	\$	154,630
LIABILITIES AND STOCKHOLDERS EQUITY			
Current Liabilities:			
Accounts payable	\$ 9,749	\$	8,792
Accrued compensation	7,532		7,702
Advance payments from customers	1,062		9,124
Accrued liabilities	5,276		5,174
Deferred service revenue	10,298		7,707
Deferred gross profit	15,308		13,964
Obligation resulting from sale of receivables	398		1,093
Total current liabilities	49,623		53,556
Long-term deferred service revenue	14,676		10,083
Other long-term liabilities	327		995
Total Liabilities	64,626		64,634
Stockholders equity	230,288		89,996
Total Liabilities and Stockholders Equity	\$ 294,914	\$	154,630

(1) Information derived from our December 31, 2006 audited Consolidated Financial Statements.

The accompanying notes are an integral part of these condensed consolidated financial statements.

OMNICELL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2007	2006	2007	2006
Revenues:				
Product	\$ 46,376	\$ 33,239	\$ 129,271	\$ 88,202
Services and other revenues	8,776	7,992	25,864	23,422
Total revenue	55,152	41,231	155,135	111,624
Cost of revenues:				
Cost of product revenues	20,479	15,383	58,776	40,511
Cost of services and other revenues	4,860	3,317	13,955	9,714
Total cost of revenues	25,339	18,700	72,731	50,225
Gross profits	29,813	22,531	82,404	61,399
Operating expenses:				
Research and development	3,848	2,878	10,999	7,858
Selling, general, and administrative	20,732	16,736	58,497	48,031
Total operating expenses	24,580	19,614	69,496	55,889
Income from operations	5,233	2,917	12,908	5,510
Other income and expense	2,055	583	4,075	1,277
	7,288	3,500	16,983	6,787
Income before provision for (benefit from) income taxes				
Provision for (benefit from) income taxes	348	384	(12,015)	522
Net income	6,940	3,116	28,998	6,265
Net income per share:				
Basic	\$ 0.20	\$ 0.11	\$ 0.93	\$ 0.23
Diluted	\$ 0.19	\$ 0.11	\$ 0.88	\$ 0.22
Shares used in computing net income per share:				
Basic	34,127	27,775	31,278	27,336
Diluted	35,833	29,450	32,996	28,795

The accompanying notes are an integral part of these condensed consolidated financial statements.

OMNICELL, INC.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(In thousands, unaudited)

	Nine Months Ended September 30	
	2007	2006
Operating activities:		
Net income	\$28,998	\$6,265
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	2,705	2,813
Provision for receivable reserves	413	283
Share-based stock compensation expense	8,016	6,116
Loss on sale of property and equipment	11	60
Provision for excess and obsolete inventories	1,433	2,074
Deferred taxes	(12,783)	
Income tax benefits from employee stock option exercises	218	(106)
Changes in operating assets and liabilities:		
Accounts receivable, net	(13,319)	(3,494)
Inventories	1,563	(10,053)
Prepaid expenses	(1,240)	(2,229)
Other current assets	2,706	(5,948)
Non-current investment in sales-type leases	987	(8,788)
Other non-current assets	(3,634)	7,444
Accounts payable	957	3,290
Accrued compensation	(696)	(771)
Advance customer payments	(8,062)	638
Accrued liabilities	42	5,129
Deferred service revenue	7,184	1,012
Deferred gross profit	1,344	6,260
Other long-term liabilities	(668)	419
Net cash provided by operating activities	16,175	10,414
Investing activities:		
Acquisition of intangible and intellectual property	(244)	(677)
Purchases of short-term investments		(12)
Purchases of property and equipment	(4,748)	(2,056)
Net cash used in investing activities	(4,992)	(2,745)
Financing activities:		
Issuance of stock under employee stock purchase plan and stock option exercises	13,491	
Net proceeds from public offering of common stock	90,218	12,876
Net cash provided by financing activities	103,709	12,876
Net increase in cash and cash equivalents	114,892	20,545
Cash and cash equivalents at beginning of period	60,856	29,536
Cash and cash equivalents at end of period	175,748	50,081

The accompanying notes are an integral part of these condensed consolidated financial statements.

OMNICELL, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1. Overview

Description of the Company.

Omniceil, Inc. (Omnicell, our, us, we, or the Company) was incorporated in California in 1992 under the name Omnicell Technologies, Inc. reincorporated in Delaware in 2001 as Omnicell, Inc. Our major products are medication and supply dispensing systems which are sold in our principal market, which is the healthcare industry. Our market is primarily located in the United States.

Basis of Presentation and Summary of Significant Accounting Policies

These interim condensed consolidated financial statements are unaudited but reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of Omnicell and its subsidiaries as of September 30, 2007, and the results of operations for the three and nine month periods ended September 30, 2007 and 2006 and cash flows for the nine month periods ended September 30, 2007 and 2006. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles, or GAAP, have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission, or SEC. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company's Annual Report on Form 10-K as of, and for, the year ended December 31, 2006. Certain prior period amounts in our Condensed Consolidated Statement of Cash Flows have been reclassified to conform to the current period presentation. Amounts reclassified include prepaid expenses, other current assets, investment in sales-type leases, other non-current assets, accrued compensation and advance payments from customers.

Our results of operations for the three and nine months ended September 30, 2007 and cash flows for the nine month period ended September 30, 2007 are not necessarily indicative of results that may be expected for the year ending December 31, 2007, or for any future period.

Use of estimates. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Principles of consolidation. The consolidated financial statements include the accounts of our wholly-owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation.

Sales of accounts receivable. We offer our customers multi-year, non-cancelable payment terms. For the three and nine months ended September 30, 2007, sales of medication and supply dispensing systems sold with multi-year payment terms totaled approximately \$17.7 million and \$45.9 million, respectively. Sales of medication and supply dispensing systems sold with multi-year payment terms totaled approximately \$8.7 million and \$31.5 million, respectively, for comparable periods in 2006. Generally we sell non-U.S. government receivables to third-party leasing companies on a non-recourse basis. We reflect the financing costs on the sale of these receivables as a component of our revenue. We record our revenue at the net present value of the multi-year payment stream using the contractual interest rate charged to us by the third-party leasing company. We record the sale of the accounts receivables as true sales in accordance with Statement of Financial Accounting Standards, or SFAS No. 140, Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities. During the nine months ended September 30, 2007 and 2006, we transferred non-recourse accounts receivable totaling \$41.5 million and \$25.9 million, respectively, which approximated fair value, to leasing companies on a non-recourse basis. At September 30, 2007 and December 31,

2006, accounts receivable included \$2.0 million and \$3.7 million, respectively, from leasing companies for transferred non-recourse accounts receivable. Due to the nature of the recourse clauses in certain of our sales arrangements, we recorded \$0.7 million as of September 30, 2007 and \$1.8 million as of December 31, 2006 as receivables subject to a sales agreement and obligation resulting from sale of receivables due to recourse clauses in those certain sale arrangements.

Dependence on key suppliers. We have a supply agreement with a supplier for construction and supply of several sub-assemblies and inventory management of sub-assemblies used in our hardware products. There are no minimum purchase requirements. The sub-section of the contract for construction and supply of assemblies may be terminated by either the supplier or by us without cause and at any time upon giving approximately four months' notice. The sub-section of the contract for inventory management of assemblies may be terminated by either the supplier or by us without cause and at any time upon giving approximately six months' notice. Purchases from this supplier for the three and nine months ended September 30, 2007 were approximately \$4.9 million and \$10.6 million, respectively. We expect our third-party manufacturing supplier to build a substantial portion of the sub-assemblies which we previously built at our manufacturing facility in California. We anticipate reducing our risk of dependence on a single-source supplier by establishing additional supplier manufacturing relationships and by securing single-source supplier secondary manufacturing sites.

Income Taxes. For the nine months ended September 30, 2007, we recorded an income tax benefit of \$12.0 million as compared with an income tax expense of \$0.5 million for the corresponding period in fiscal 2006. The tax benefit for the nine months ended September 30, 2007 primarily resulted from a partial release of the valuation allowance carried against our deferred tax assets. The tax expense for the period ended September 30, 2006 was recorded for taxes due on minimum and alternative minimum state taxes and alternative minimum federal taxes.

During the nine months ended September 30, 2007, we determined that it was more likely than not that we would have sufficient future taxable income to utilize a portion of our deferred tax assets and, as a result, we released approximately \$12.8 million of valuation allowance against these assets during the second quarter of 2007. For interim reporting, the effect of a change in judgment about the realizability of deferred tax assets should be recognized as of the date of the change. The effective tax rate for subsequent interim periods for the remainder of the year should not be affected by this change in judgment. We will continue to evaluate our ability to realize our deferred tax asset on a quarterly basis and adjust the valuation allowance against these deferred tax assets accordingly.

We believe there is a risk associated with our ability to utilize net operating losses, or NOLs, and have retained a valuation allowance of \$24.9 million offsetting net deferred tax assets as of September 30, 2007. SFAS No. 109, *Accounting for Income Taxes*, or SFAS No. 109 requires us to evaluate the realization of our deferred tax assets. Circumstances leading to a change in judgment about our deferred tax assets included a secondary stock offering in May 2007 which provided funding for additional growth opportunities, utilization of NOLs, recent cumulative history of profitability and a favorable near term business forecast. These items, taken collectively lead us to believe a portion of our deferred tax assets will be realized. The remaining portion of the deferred tax assets will remain subject to a valuation allowance until future circumstances indicate they may be realized. The remaining deferred tax assets subject to a valuation allowance include temporary book-tax differences and NOLs related to stock options. These NOLs are approximately \$9.9 million and the valuation allowance will be released when the NOLs are utilized to reduce cash taxes and an associated benefit will be to additional paid-in capital. Approximately \$2.2 million of operating losses are fully offset by a valuation allowance due to limitations imposed by Internal Revenue Code Section 382.

Other comprehensive income. Other comprehensive income is the same as net income for the three and nine months ended September 30, 2007 and 2006.

Segment Information. We manage our business on the basis of one reportable segment. Our products and technologies share similar distribution channels and customers and are sold primarily to hospitals and healthcare facilities to improve patient safety and care and enhance operational efficiency. Our sole operating segment is medication and supply dispensing systems. Substantially all of our long-lived assets are located in the United States. For the three and nine months ended September 30, 2007 and 2006, substantially all of our total revenues and gross profits were generated by the medication and supply dispensing systems operating segment from customers in the United States.

Newly Issued Accounting Standards. In February 2007, the Financial Accounting Standards Board, or FASB, issued SFAS No. 159, *The Fair Value Option for Financial Assets and Financial Liabilities*, or SFAS No. 159, which includes an amendment of FASB Statement No. 115, *Accounting for Certain Investments in Debt and Equity Securities*. SFAS No. 159 expands the scope of what companies may carry at fair value and permits entities to choose, at specified election dates, to measure financial assets and financial liabilities at their fair value with related unrealized gains or losses recorded in earnings. SFAS No. 159 is effective for fiscal years beginning after November 15, 2007; however, in certain circumstances, earlier adoption is permitted. We are currently evaluating the impact of SFAS No. 159 on our consolidated statements of financial position, results of operations or cash flows.

Edgar Filing: OMNICELL, Inc - Form 10-Q

In September 2006, FASB issued SFAS No. 157, Fair Value Measurements, or SFAS No. 157, which defines fair value, establishes guidelines for measuring fair value and expands disclosures regarding fair value measurements. SFAS No. 157 does not require any new fair value measurements but rather eliminates inconsistencies in guidance found in various

prior accounting pronouncements. SFAS No.157 is effective for fiscal years beginning after November 15, 2007. Earlier adoption is permitted, provided the company has not yet issued financial statements, including for interim periods, for that fiscal year. We are currently evaluating the impact of SFAS No. 157 on our consolidated statements of financial position, results of operations and cash flows.

Note 2. Net Income Per Share

Edgar Filing: OMNICELL, Inc - Form 10-Q

Basic net income per share is computed by dividing net income for the period by the weighted-average number of shares outstanding during the period, less shares subject to repurchase. Diluted net income per share is computed by dividing net income for the period by the weighted-average number of shares less shares subject to repurchase plus, if dilutive, common stock equivalent shares outstanding during the period. Common stock equivalents include the effect of outstanding dilutive stock options and restricted stock units computed using the treasury stock method. The calculation of basic and diluted net income per share is as follows (in thousands, except per share amounts):

	Three Months Ended September 30.		Nine Months Ended September 30.	
	2007	2006	2007	2006
Basic:				
Net income	\$ 6,940	\$ 3,116	\$ 28,998	\$ 6,265
Weighted average shares outstanding-basic	34,127	27,775	31,278	27,336
Net income per share-basic	\$ 0.20	\$ 0.11	\$ 0.93	\$ 0.23
Diluted:				
Net income	\$ 6,940	\$ 3,116	\$ 28,998	\$ 6,265
Weighted average shares of common stock outstanding	34,127	27,775	31,278	27,336
Add: Dilutive effect of employee stock options and restricted stock units	1,706	1,675	1,718	1,459
Weighted average shares outstanding diluted	35,833	29,450	32,996	28,795
Net income per share-diluted	\$ 0.19	\$ 0.11	\$ 0.88	\$ 0.22

Note 3. Stockholders Equity and Stock Option Plans

Share Purchase Rights Plan

Edgar Filing: OMNICELL, Inc - Form 10-Q

On February 6, 2003, our board of directors approved the adoption of a Share Purchase Rights Plan, or the Rights Plan. Terms of the Rights Plan provide for a dividend distribution of one preferred share purchase right, or a Right, for each outstanding share of our common stock, par value \$0.001 per share. The dividend was payable on February 27, 2003 to the stockholders of record on that date.

The Rights are not exercisable until the distribution date, which is the earlier of the date of a public announcement that a person, entity or group of affiliated or associated persons have acquired beneficial ownership of 15% or more of the outstanding share of our common stock (an Acquiring Person) or (ii) 10 business days (or such later date as may be determined by action of the board of directors prior to such time as any person or entity becomes an Acquiring Person) following the commencement of, or announcement of an intention to commence, a tender offer or exchange offer the consummation of which would result in any person or entity becoming an Acquiring Person. In the event that any person or group of affiliated or associated persons becomes an Acquiring Person or a tender offer is commenced or announced to commence, each stockholder holding a Right will thereafter have the right to receive upon exercise of the Right that number of shares of Common Stock having a market value of two times the exercise price of the Right. The description and terms of the Rights are set forth in a Rights Agreement, dated as of February 6, 2003 entered into between us and EquiServe Trust Company, N.A., as rights agent. Sutter Hill Ventures and ABS Capital Partners and their respective affiliated entities will be exempt from the Rights Plan, unless they acquire beneficial ownership of 17.5% or 22.5% or more, respectively, of the Company's common stock. At no time will the Rights have any voting power. The Rights will expire on February 27, 2013, unless the Rights are earlier redeemed or exchanged by Omnicell.

Description of Share-Based Plans

Edgar Filing: OMNICELL, Inc - Form 10-Q

Stock Option Plans. Our 1999 Equity Incentive Plan, or the 1999 Plan, was adopted in September 1999 for the granting of incentive and nonqualified stock options, restricted stock units, or RSUs, and rights to purchase common stock and common stock units to employees, directors and consultants. RSUs give the recipients the right to receive shares of our stock upon the lapse of their related restrictions. Restrictions on RSUs lapse in various increments beginning from date of grant. Under the 1999 Plan, 4,262,745 shares of common stock were initially authorized for issuance. Further, all unissued shares under our 1992 Stock Plan and 1995 Management Stock Option Plan were added to the 4,262,745 shares reserved under the 1999 Plan. Under all of the option plans, incentive and nonqualified stock options or rights to purchase common stock may be granted to employees, directors and consultants. Incentive options, nonqualified options and stock purchase rights must be priced to be at least 100%, 85% and 85%, respectively, of the common stock's fair market value at the date of grant. Options shall become exercisable as determined by our board of directors. Options granted under the 1999 Plan generally become exercisable over periods of up to four years, generally with one-fourth of the shares vesting one year from the vesting commencement date with respect to initial grants, and the remaining shares vesting in 36 equal monthly installments thereafter; however our board of directors may impose different vesting terms at its discretion on any award. Options under the 1999 Plan generally expire ten years from the date of grant. Sales of stock under stock purchase rights are made pursuant to restricted stock purchase agreements.

In October 2006, the 1999 Plan was amended to permit grants of restricted stock and restricted stock units to participants under the 1999 plan. The board of directors determines the price, which is equal to the market price of the stock on the date of the grant, the award amount, the vesting provisions and the expiration period (not to exceed ten years) for each grant. We consider the dilutive impact of this program in our diluted net income per share calculation.

The fair value of restricted stock under the 1999 Plan is the product of the number of shares granted and the grant date market price of our common stock on the grant date. Expected future compensation expense relating to restricted shares outstanding is \$0.2 million. A summary of activity of restricted stock granted under the 1999 Plan as of September 30, 2007 is presented below:

	Shares of Restricted Stock (in thousands)	Weighted- Average Grant Date Fair Value Per Share
Nonvested at December 31, 2006	17	\$ 18.85
Granted	15	22.63
Vested	(18)	18.99
Forfeited or cancelled		
Nonvested at September 30, 2007	14	\$ 22.63

RSUs granted to employees generally vest over a period of four years and are expensed ratably on a straight-line basis over the vesting period.

RSUs granted to non-employee directors are granted on the date Omnicell's annual meeting of stockholders and vest in full on the date of Omnicell's next annual meeting of stockholders and are expensed ratably on a straight-line basis over the vesting period. The fair value of RSUs under the 1999 plan is the product of the number of shares granted and the grant date market price of our common stock on the grant date. Expected future compensation expense relating to RSUs outstanding on September 30, 2007 is \$2.7 million over a weighted-average period of four years. A summary of activity of restricted stock units granted under the 1999 Plan as of September 30, 2007 is presented below:

	Restricted Stock Units (in thousands)	Weighted- Average Grant Date Fair Value
Nonvested at December 31, 2006	15	\$ 19.91
Granted	132	21.61
Vested	(10)	20.95
Forfeited or cancelled	(8)	20.95
Nonvested at September 30, 2007	129	\$ 21.50

On January 1 of each year, the number of shares reserved for issuance under the 1999 Plan increases automatically by the lesser of (i) 5.5% of the total number of shares of our common stock outstanding, (ii) 3,000,000 shares, or (iii) such other lesser amount as may be determined by our board of directors. As of September 30, 2007, there were a total of 1,590,083 shares reserved for future issuance under the 1999 Plan.

Edgar Filing: OMNICELL, Inc - Form 10-Q

In April 2003, our board of directors adopted the 2003 Equity Incentive Plan, or the 2003 Plan. A total of 500,000 shares of common stock has been reserved for issuance under the 2003 Plan. As of September 30, 2007, 343,073 shares were subject to outstanding options under the 2003 Plan. As of September 30, 2007, there were a total of 140,070 shares reserved for future issuance under the 2003 Plan. The 2003 Plan provides for the issuance of non-qualified options, stock bonuses and rights to acquire restricted stock to our employees, directors and consultants. Options granted under the 2003 Plan shall have an exercise price not less than 70% of the fair market value of the stock on the date of grant and are generally intended to become exercisable over periods of up to four years, generally with one-fourth of the shares vesting one year from the vesting commencement date with respect to initial grants, and the remaining shares vesting in 36 equal monthly installments thereafter, however our board of directors may impose different vesting at its discretion on any award. Options granted under the 2003 Plan will expire ten years from the date of grant.

In February 2004, our board of directors adopted the 2004 Equity Incentive Plan, or the 2004 Plan and, together with the 1999 Plan and the 2003 Plan, the Plans. A total of 200,000 shares of common stock has been reserved for issuance under the 2004 Plan. No options are currently issued or outstanding under the 2004 Plan. The 2004 Plan provides for the issuance of non-qualified options to new employees as an inducement material to the individual s entering into employment with us. Options granted under the 2004 Plan have an exercise price not less than the fair market value of the stock on the date of grant and generally become exercisable over periods of up to four years, generally with one-fourth of the shares vesting one year from the vesting commencement date with respect to initial grants, and the remaining shares vesting in 36 equal monthly installments thereafter; however our board of directors may impose different vesting terms at its discretion on any award. Options under the 2004 Plan generally expire ten years from the date of grant.

The board of directors shall administer the Plans unless and until the board of directors delegates administration to a committee. The Board has delegated administration of the Plans to the Compensation Committee of the Board and the Plans are generally administered by such committee. The board of directors may suspend or terminate the Plans at any time. The board of directors may also amend any of the Plans at any time or from time to time. However, no amendment will be effective unless approved by our stockholders after its adoption by the board of directors to the extent stockholder approval is necessary to satisfy the requirements of The NASDAQ Stock Market listing requirements.

If we sell, lease or dispose of all or substantially all assets or we are acquired pursuant to a merger or consolidation, then the surviving entity may assume or substitute all outstanding awards under the Plans. If the surviving entity does not assume or substitute these awards, then generally the vesting and exercisability of the stock awards will accelerate.

A summary of option activity under the Plans as of September 30, 2007 is presented below:

Options:	Number of Shares (in thousands)	Weighted- Average Exercise Price
Outstanding at December 31, 2006	5,238	\$ 9.85
Granted	912	21.52
Exercised	(1,263)	8.97
Cancelled	(201)	13.86
Forfeited	(25)	16.42
Outstanding at September 30, 2007	4,661	12.16
Exercisable at September 30, 2007 (1)	2,770	\$ 9.75

(1) Exercisable options are fully vested as of September 30, 2007.

Outstanding options at September 30, 2007 had a weighted-average remaining contractual life of 6.7 years and an aggregate intrinsic value of \$76.3 million. Exercisable options at September 30, 2007 had an aggregate intrinsic value of \$52.2 million. At September 30, 2007, there was \$10.6 million of total unrecognized compensation cost related to non-vested stock options.

For the nine months ended September 30, 2007, the aggregate intrinsic value of options exercised was \$16.8 million and the weighted-average fair value of options exercised was \$8.97.

Edgar Filing: OMNICELL, Inc - Form 10-Q

At September 30, 2007, the total number of shares available for future issuance under all Plans was as follows (in thousands):

Reserved under the Plans	1,930
Reserved under the 1997 Employee Stock Purchase Plan	832
Total	2,762

1997 Employee Stock Purchase Plan. We have an Employee Stock Purchase Plan, or ESPP, under which employees can purchase shares of our common stock based on a percentage of their compensation, but not greater than 15% of their earnings, up to a maximum of \$25,000 of fair value per year. The purchase price per share must be equal to the lower of 85% of the fair value of the common stock at the beginning of a 24-month offering period or the end of each six-month purchasing period. As of September 30, 2007, 1,876,968 shares had been issued under the ESPP. On January 1 of each year, the number of shares reserved for issuance under the ESPP increases automatically by the lesser of (i) 1.5% of the total number of shares of our common stock outstanding, (ii) 750,000 shares, or (iii) such other lesser amount as may be determined by our board of directors. As of September 30, 2007, there were a total of 832,161 shares reserved for future issuance under the ESPP.

Secondary Offering

In May 2007, we issued 4,485,000 shares of our common stock in a public offering at an offering price of \$21.50 per share. The net proceeds to us were \$90.2 million, which is net of both underwriting discounts and offering expenses of \$6.2 million.

Note 4. Share-Based Compensation

We follow the provisions of SFAS 123(R), Share-Based Payment, or SFAS No. 123(R), for share-based awards granted to employees and directors including employee stock option awards, restricted stock and RSUs and employee stock purchases made under our ESPP using the estimated grant date fair value method of accounting in accordance with SFAS No. 123(R).

The impact on our results for share-based compensation was as follows (in thousands, except per share data):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2007	2006	2007	2006
Cost of product and services	\$ 294	\$ 304	\$ 1,028	\$ 828
Research and development	201	153	692	512
Selling, general and administrative	2,321	1,593	6,357	4,776
Total share-based compensation expense	\$ 2,816	\$ 2,050	\$ 8,077	\$ 6,116

Share-based compensation capitalized in inventory at September 30, 2007 and 2006 was \$61,000 and \$11,000, respectively.

Note 5. Inventories

Edgar Filing: OMNICELL, Inc - Form 10-Q

Inventories consist of the following (in thousands):

	September 30, 2007		December 31, 2006	
Raw materials	\$	8,883	\$	11,809
Work in process		401		95
Finished goods		3,381		3,820
Total	\$	12,665	\$	15,724

During the three and nine months ended September 30, 2007, we increased our provision for excess and obsolete inventories by \$0.2 million and \$1.4 million, respectively.

Note 6. Net Investment in Sales-Type Leases

Edgar Filing: OMNICELL, Inc - Form 10-Q

Our sales-type leases are for terms generally ranging up to five years. Sales-type lease receivables are collateralized by the underlying equipment. The components of our net investment in sales-type leases are as follows (in thousands):

	September 30, 2007	December 31, 2006
Net minimum lease payments to be received	\$ 17,298	\$ 17,949
Less unearned interest income portion	2,728	2,849
Net investment in sales-type leases	14,570	15,100
Less current portion(1)	3,313	2,856
Non-current net investment in sales-type leases(2)	\$ 11,257	\$ 12,244

The minimum lease payments under sales-type leases as of September 30, 2007:

2007 (remaining amount)	\$ 2,109
2008	4,529
2009	4,195
2010	3,486
2011	2,159
Thereafter	820
Total	\$ 17,298

(1) A component of other current assets

(2) Net of allowance for doubtful accounts of \$0.3 million as of September 30, 2007 and December 31, 2006.

Note 7. Other Assets

Edgar Filing: OMNICELL, Inc - Form 10-Q

Other assets consist of the following (in thousands):

	September 30, 2007	December 31, 2006
Long-term deposits	\$ 398	\$ 353
Goodwill and net purchased intangible assets (see Note 8)	4,480	4,924
Equity investment, at cost	350	350
Long-term lease receivable from sales of accounts receivables under SFAS No. 140 (see Note 1)	253	670
Capitalized software development costs, net of accumulated amortization of \$600 and \$600 in 2007 and 2006, respectively	621	1,071
Non-current deferred service billings receivable	6,296	1,773
Other non-current assets	135	202
Other assets	\$ 12,533	\$ 9,343

Note 8. Goodwill and Net Purchased Intangibles

Edgar Filing: OMNICELL, Inc - Form 10-Q

Intangible assets consist of the following (in thousands):

	September 30, 2007		December 31, 2006		Amortization Life
Customer base	\$	244	\$	244	5 years
Service contracts		268		268	5 years
Patents and trademarks		243			5 years
Acquired technology		5,084		5,084	3-6 years
Total purchased intangible assets with finite lives		5,839		5,596	
Accumulated amortization		(4,717)		(4,030)	
Net purchased intangible assets		1,122		1,566	
Goodwill		3,127		3,127	Indefinite
Trade name		231		231	Indefinite
Goodwill and net purchased intangible assets	\$	4,480	\$	4,924	

Edgar Filing: OMNICELL, Inc - Form 10-Q

Intangible assets increased by \$0.2 million for the nine months ended September 30, 2007 as a result of additional investment in patents and patent filing costs. Amortization expense totaled \$0.2 million and \$0.7 million for the three and nine months ended September 30, 2007, respectively. Amortization expense was \$0.2 million and \$0.8 million for the same periods during 2006. Estimated annual expected amortization expense of intangible assets at September 30, 2007 is as follows (in thousands):

2007 (remaining amount)	\$	224
2008		617
2009		201
2010		80
Total	\$	1,122

Note 9. Deferred Gross Profit

Edgar Filing: OMNICELL, Inc - Form 10-Q

Deferred gross profit consists of the following (in thousands):

	September 30, 2007	December 31, 2006
Sales of medication and supply dispensing systems, which have been delivered and invoiced but not yet installed	\$ 26,544	\$ 21,858
Cost of sales, excluding installation costs	(11,236)	(7,894)
Deferred gross profit	\$ 15,308	\$ 13,964

Note 10. Accrued Liabilities

Edgar Filing: OMNICELL, Inc - Form 10-Q

Accrued liabilities consist of the following (in thousands):

	September 30, 2007	December 31, 2006
Accrued GPO fees	\$ 1,533	\$ 1,584
Deferred rent	826	1,038
Accrued professional fees	541	1,179
Sales and use taxes payable	1,270	589
Customer refunds	929	629
Other	177	155
Total	5,276	\$ 5,174

Note 11. Commitments and Contingencies

Contractual Obligations

Edgar Filing: OMNICELL, Inc - Form 10-Q

The following table summarizes our contractual obligations at September 30, 2007 (in thousands):

	Total	Less than one year	One to three years	Three to five years	More than five years
Operating leases(1)	\$ 7,425	\$ 665	\$ 4,489	\$ 1,855	\$ 416
Commitments to contract manufacturers and suppliers(2)	1,239	1,239			
Other contractual obligations(3)	175	175			
Total	\$ 8,839	\$ 2,079	\$ 4,489	\$ 1,855	\$ 416

(1) Commitments under operating leases relate primarily to leasehold property.

(2) We purchase components from a variety of suppliers and use contract manufacturers to provide manufacturing services for our products. During the normal course of business, we issue purchase orders with estimates of our requirements several months ahead of the delivery dates. We record a liability for firm, non-cancelable, and unconditional purchase commitments.

(3) As part of the December 2002 acquisition of substantially all of the intellectual properties of Medisafe, we agreed to pay \$0.5 million in guaranteed minimum royalties due over four years in equal annual installments of \$125,000 beginning January 2005. Also included is a lease deposit of \$50,000.

Indemnification Arrangements and Guarantees. As permitted under Delaware law and our amended and restated bylaws and amended and restated certificate of incorporation, we have agreements whereby we indemnify our officers and directors for certain events or occurrences while the officer or director is or was serving at our request in such capacity. The term of the indemnification period is for the officer's or director's lifetime. The maximum potential amount of future payments they could be required to make under these indemnification agreements is unlimited; however, we have a directors' and officers' insurance policy that may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage and the willingness of the insurer to assume coverage and subject to certain retention, loss limits and other policy provisions, we believe it is unlikely that we will be required to pay any material amounts pursuant to this indemnification obligation. However, no assurances can be given that the insurers will not attempt to dispute the validity, applicability or amount of coverage without expensive and time-consuming litigation against the insurers.

Additionally, we undertake indemnification obligations in the ordinary course of business in connection with, among other things, the licensing of our products and the provision of our technical services. Pursuant to these agreements, we may indemnify the other party for certain losses suffered or incurred by the indemnified party, generally our business affiliates or customers, in connection with various types of claims, which may include, without limitation, claims of intellectual property infringement, certain tax liabilities, negligence and intentional acts in the performance of services and violations of laws. The term of these indemnification obligations is generally perpetual. In general, we attempt to limit the maximum potential amount of future payments which we may be required to make under these indemnification obligations to the purchase price paid, but in some cases the obligation may not be so limited. In addition, we may, in certain situations, warrant that, for a certain period of time from the date of delivery, our software products will be free from defects in media or workmanship. From time to time, it may also warrant that our professional services will be performed in a good and workmanlike manner. In addition, it is our standard policy to seek to disclaim most warranties, including any implied or statutory warranties such as warranties of merchantability, fitness for a particular purpose, quality and non-infringement, as well as any liability with respect to incidental, consequential, special, exemplary, punitive or similar damages. In some states, such disclaimers may not be enforceable. If necessary, we would provide for the estimated cost of product and service warranties based on specific warranty claims and claim history. However, in the recent past, we have not been subject to any significant claims for such losses and have not incurred any material costs in defending or settling claims related to these indemnification obligations. Accordingly, we believe it is unlikely that we will be required to pay any material amounts pursuant to this indemnification obligation.

Legal Proceedings

Edgar Filing: OMNICELL, Inc - Form 10-Q

On February 20, 2007, we were served with the third amended petition in a lawsuit entitled Alcala, et al. v. Cardinal Health, Inc., et al., case number 2006 09-4487-G, which named us as a defendant. This lawsuit was filed in the District Court of Cameron County, Texas. The lawsuit alleges claims against us for strict products liability, negligence and gross negligence arising from the use of our product by defendant Cardinal Health 109, Inc. in connection with the treatment of a patient who died after receiving treatment. The petition, which was filed by the family and estate of the deceased patient, alleges that defects in the design of our product contributed to the patient's death which was allegedly caused by the administration of the wrong medication. We deny any liability, have engaged our insurance carrier on this matter and intend to vigorously defend against these claims.

Note 12. Accounting Changes

In July 2006, the FASB issued FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes-an interpretation of SFAS No. 109, or FIN 48. FIN 48 clarifies the accounting for uncertainty in income taxes and interprets the provision of FASB Statement No. 109. FIN 48 is effective prospectively for fiscal years beginning after December 15, 2006. We adopted the provisions of FIN 48 beginning on January 1, 2007. We recorded a \$0.1 million cumulative effect of adopting FIN 48 as a charge to the opening balance of retained earnings as of January 1, 2007. The non-current liability for uncertain tax positions includes: a) a reclassification of our FASB No. 5, Accounting for Contingencies, or SFAS No. 5, reserves, which meet recognition and measurement requirements of FIN 48; b) a tax reserve resulting from adoption of FIN 48 and c) an increase for interest expense and penalties on the uncertain tax positions. At September 30, 2007, current accruals with respect to tax reserves, interest and penalties on uncertain tax positions were not significant. Interest and penalties were recorded as other income and expense in the Condensed Consolidated Statement of Operations for the three and nine months ended September 30, 2007, in accordance with our election under FIN 48. Effects on our income tax provision as a result of the resolution of tax uncertainties were not significant. We expect further changes in our tax reserve balance in the next 12 months as a result of expiration of the statute of limitations related to foreign tax filings. These changes may result in decrease in the total amount of unrecognized tax liability of less than \$0.1 million.

Our tax years 1995 to 2006 remain open to audit by the Internal Revenue Service. A tax reserve of \$0.1 million will impact our effective tax rate upon resolution of the uncertainties, which is not expected to be material. No material impact is expected to other comprehensive income, goodwill, or additional paid-in capital upon release of the liability.

In June 2006, the FASB issued Emerging Issues Task Force No. 06-2, Accounting for Sabbatical Leave and Other Similar Benefits Pursuant to FASB Statement No. 43, or EITF No. 06-2, which requires measurement of compensation costs associated with a sabbatical or other similar benefit arrangement over the requisite service period if the obligation relates to rights that vest or accumulate.

We adopted the provisions of EITF No. 06-2 beginning on January 1, 2007, which allows for adoption under the retrospective method or as a change in accounting principle through a cumulative-effect adjustment to retained earnings. We presented the change in accounting principle through a cumulative-effect adjustment of \$0.5 million to the opening balance of retained earnings as of January 1, 2007. As required by EITF No. 06-2, compensation costs associated with sabbatical leave is recorded for all employees after the adoption of the provisions of EITF No. 06-2 on a straight-line basis over the four year accumulation period. These expenses totaled \$0.1 million and \$0.5 million for the three and nine months ended September 30, 2007, respectively.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about:

the extent and timing of future revenues;

the size and/or growth of our market or market-share;

the opportunity presented by new products or emerging markets;

the operating margins or earnings per share goals we may set;

our ability to manage our growth;

our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; and

our estimates regarding the sufficiency of our cash resources.

In some cases, you can identify forward-looking statements by terms such as anticipates, believes, could, estimates, expects, intends, may, potential, predicts, projects, should, will, would, and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events, are based on assumptions, and are subject to risks and uncertainties. We discuss many of these risks in this Quarterly Report on Form 10-Q in greater detail in Part II Section 1A. Risk Factors below. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q.

You should also read our Annual Report on Form 10-K and the documents that we reference in the Annual Report on Form 10-K and have filed as exhibits, completely and with the understanding that our actual future results may be materially different from what we expect.

Edgar Filing: OMNICELL, Inc - Form 10-Q

Except as required by law, we assume no obligation to update any forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, even if new information becomes available in the future. The following discussion should be read in conjunction with the unaudited condensed consolidated financial statements and notes included elsewhere in this report.

Overview

Edgar Filing: OMNICELL, Inc - Form 10-Q

We were incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. Our healthcare automation solutions are designed to enable healthcare facilities to acquire, manage, dispense and administer medications and medical-surgical supplies, and are intended to enhance patient safety, reduce medication errors, improve workflow and increase operational efficiency. When used in combination, our products and services provide healthcare facilities with a comprehensive solution designed to enhance patient safety and improve operational efficiency.

We sell our medication dispensing and supply automation systems, and generate substantially all our revenue, in the United States. Our sales force is organized by geographic region in the United States and Canada. We also sell through distributors in Asia, Australia, Europe, the Middle East and South America. In 2006, we manufactured the majority of our systems in our California facility and refurbishment and spare parts activities were conducted in our Illinois facility. In November 2006, we began manufacturing sub-assemblies at a single-source manufacturing supplier to provide increased manufacturing capacity. We also increased our inventory levels in 2006, allowing for greater levels of installations. In 2005, we established a subsidiary in India, Omnicell Corporation (India) Private Limited. This subsidiary is focused on software product development and customer support. A substantial number of our U.S. employees involved in sales, customer support and installation work remotely.

In general, we recognize revenue when our medication dispensing and supply automation systems are installed. Installation generally takes place six to nine months after our systems are ordered. The installation process at our customers' sites includes internal procedures associated with large capital expenditures and additional time associated with adopting new technologies. Given the length of time necessary for our customers to plan for and complete their acceptance of the installation of our systems, our focus is on shipping products based on the installation dates requested by our customers and working at the customer's pace. The amount of revenue recognized in future periods may depend on, among other things, the terms and timing of lease contract renewals, additional product sales and the size of such transactions. We believe that future revenue will be affected by the competitiveness of our products and services.

Trends in Our Business

Edgar Filing: OMNICELL, Inc - Form 10-Q

Revenues for the three months ended September 30, 2007 increased to \$55.2 million, up from \$41.2 million for the same period in 2006. Revenues for the nine months ended September 30, 2007 increased to \$155.1 million, up from \$111.6 million for the same period in 2006. We believe that three factors were primarily responsible for this growth:

We have continued to differentiate ourselves through a strategy intended to create the best customer experience in healthcare;

We have delivered products with differentiated features that are designed to appeal to nurses and pharmacists; and

The market environment of increased patient safety awareness and increased regulatory control has driven automation to be a priority in healthcare facilities' capital budgets.

Our product backlog grew to \$140.6 million at September 30, 2007 from \$113.8 million at December 31, 2006, as customer orders for our products continued to grow at a faster pace than we installed customer orders. Our customers require well-planned installations that provide them with a minimal amount of disruption. Installations, which coincide with full delivery of our obligations to our customers and therefore represent our point of revenue recognition, can take place anywhere from one week to 12 months or longer after an order is received for our products. Given our customers' often lengthy installation schedules, we believe our current backlog level is appropriate for our industry.

In the nine months ended September 30, 2007, operating activities provided \$16.2 million of cash. This increase is due to our expenses growing slower than the rate of our revenue growth combined with working capital from operations. We also used \$5.0 million in cash in investing activities for purchases of property and equipment and investments in intellectual property. Proceeds from financing consisted of \$13.5 million of cash from issuances of common stock pursuant to our equity incentive plans and employee stock purchase plan, and net proceeds of \$90.2 million from the sale and issuance of 4,485,000 shares of our common stock in a public offering. As a result, for the nine months ended September 30, 2007, cash and cash

Edgar Filing: OMNICELL, Inc - Form 10-Q

equivalents increased from \$60.9 million at December 31, 2006 to \$175.7 million at September 30, 2007. For the nine months ended September 30, 2006, net cash generated from operations was \$10.4 million and we had a cash equivalents balance of \$50.1 million.

Our ability to grow revenue is dependent on our ability to continue to attract orders from customers, the volume of installations we are able to complete, our ability to access customer installation sites on a timely basis and our flexibility in manpower allocations among customers to complete installations on a timely basis. The revenue growth we have experienced has required a continued growth in our headcount. During the three month period ended September 30, 2007, we hired new staff members at all of our sites and in our field-based organizations, comprising mainly installation, service and support staff. Our full-time employee headcount grew 16.5% to 729 at September 30, 2007 from 626 at December 31, 2006.

Gross profit as a percentage of revenues for the three months ended September 30, 2007 declined 0.5% from the same period in 2006. Gross profit as a percentage of revenues for the nine months ended September 30, 2007 declined 1.9% compared to the same period in 2006. For the three and nine months ended September 30, 2007, the decreases in gross profit were primarily due to a larger allocation of shared operating expenses absorbed by cost of revenues, and higher infrastructure costs, such as information technology equipment and services to support our future growth. The increased allocation of shared operating expenses absorbed by cost of services and other revenues was based on our annual assessment of the allocation of shared operating expenses between various departments completed in the first fiscal quarter of 2007. As our departments associated with service and other revenues grow, an increased allocation of shared operating costs may decrease gross margin.

We do not anticipate that the decline in our gross profit represents a trend or pattern in our business. However, our gross profit could continue to decline in 2007 as compared to 2006 due to changes in the product mix sold and the continuing effect of a larger allocation of shared operating expenses absorbed by cost of revenues, as well as a result of market price reductions, additional costs to expand our business and expenses from share-based compensation expenses. This decrease in our gross profit may be wholly or partially offset by revenue growth in the fourth quarter of 2007 as compared to 2006.

We have invested in customer-facing portions of our business, in research and development and in infrastructure, but at a slower pace than demand for our products has grown. We anticipate that we will continue to invest in our business to support future growth generated by increased market demand.

We operate in one business segment, the design, manufacturing, selling and servicing of medication and supply dispensing systems. Our management team evaluates our performance based on company-wide, consolidated results.

Critical Accounting Policies and Estimates

Edgar Filing: OMNICELL, Inc - Form 10-Q

Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of any contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. We regularly review our estimates and assumptions, which are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of certain assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates and assumptions. We believe that the following critical accounting policies are affected by significant judgments and estimates used in the preparation of our consolidated financial statements:

revenue recognition,

estimating doubtful account for receivable reserves,

valuation and impairment of goodwill, purchased intangible assets and other long lived assets,

inventory valuation,

deferred tax asset valuation allowance in the accounting for taxes on income, and

share-based compensation expense.

Edgar Filing: OMNICELL, Inc - Form 10-Q

Beginning in the first quarter of 2007, we adopted the provisions of EITF Issue No. 06-2, Accounting for Sabbatical Leave and Other Similar Benefits Pursuant to FASB Statement No. 43, or EITF No. 06-2, which requires measurement of compensation costs associated with sabbatical costs. We had previously expensed sabbatical costs as incurred. We recorded a cumulative-effect adjustment of \$0.5 million to the opening balance of retained earnings as of January 1, 2007. We recognized compensation expenses associated with sabbatical leave for all employees of \$0.1 million and \$0.5 million during the three months and nine months ended September 30, 2007.

Beginning in the first quarter of 2007, we adopted FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes-an interpretation of SFAS No.109, or FIN 48, which requires recognition of a tax position in our financial statements if that position is more likely than not of being sustained on audit, based on the technical merits of the position. We recorded a cumulative-effect adjustment of \$0.1 million to the opening balance of retained earnings as of January 1, 2007. We recognized income tax benefit associated with a reduction of our FIN 48 liability of \$8,000 and \$0.1 million for the three months and nine months ended September 30, 2007.

Newly Issued Accounting Standards

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities, or SFAS No. 159, which permits entities to voluntarily choose to measure many financial instruments and certain other items at fair value. SFAS No. 159 is effective, for Omnicell, beginning January 1, 2008. We are currently evaluating the impact of SFAS No. 159 on our consolidated statements of financial position, results of operations and cash flows.

In September 2006, FASB issued SFAS No. 157, Fair Value Measurements, or SFAS No. 157, which defines fair value, establishes guidelines for measuring fair value and expands disclosures regarding fair value measurements. We are currently evaluating the impact of SFAS No. 157 on our consolidated statements of financial position, results of operations and cash flows.

Results of Operations

	Three Months Ended September 30, 2007		2006		Nine Months Ended September 30, 2007		2006	
	\$	% of Revenue	\$	% of Revenue	\$	% of Revenue	\$	% of Revenue
	(In thousands, except percentages)				(In thousands, except percentages)			
Revenues:								
Product revenue	46,376	84.1%	33,239	80.6%	129,271	83.3%	88,202	79.0%
Service and other revenues	8,776	15.9%	7,992	19.4%	25,864	16.7%	23,422	21.0%
Total revenues	55,152	100.0%	41,231	100.0%	155,135	100.0%	111,624	100.0%
Cost of revenues:								
Cost of product revenues	20,479	37.1%	15,383	37.4%	58,776	37.9%	40,511	36.3%
Cost of service and other revenues	4,860	8.8%	3,317	8.0%	13,955	9.0%	9,714	8.7%
Total cost of revenues	25,339	45.9%	18,700	45.4%	72,731	46.9%	50,225	45.0%
Gross profit	29,813	54.1%	22,531	54.6%	82,404	53.1%	61,399	55.0%
Operating expenses:								
Research and development	3,848	7.0%	2,878	7.0%	10,999	7.1%	7,858	7.0%
Selling, general and administrative	20,732	37.6%	16,736	40.6%	58,497	37.7%	48,031	43.0%
Total operating expenses	24,580	44.6%	19,614	47.6%	69,496	44.8%	55,889	50.0%
Income from operations	5,233	9.5%	2,917	7.0%	12,908	8.3%	5,510	4.9%
Interest income	2,072	3.8%	600	1.5%	4,136	2.7%	1,323	1.2%
Other expenses, net	(17)	0%	(17)	0%	(61)	0%	(46)	0%
Income before (benefit from) provision for income taxes	7,288	13.3%	3,500	8.5%	16,983	11.0%	6,787	6.1%
(Benefit from) provision for income taxes	348	0.6%	384	0.9%	(12,015)	(7.7%)	522	0.5%
Net income	6,940	12.7%	3,116	7.6%	28,998	18.7%	6,265	5.6%

Product Revenues and Gross Profit

Edgar Filing: OMNICELL, Inc - Form 10-Q

The table below shows our product revenues, cost of product revenues and gross profit for the three and nine months ended September 30, 2007 and 2006 and the percentage change between those periods:

	Three Months Ended September 30,			Nine Months Ended September 30,		
	2007	2006	% Change	2007	2006	% Change
	(in thousands)			(in thousands)		
Product revenues	\$ 46,376	\$ 33,239	39.5%	\$ 129,271	\$ 88,202	46.6%
Cost of product revenues	20,479	15,383	33.1%	58,776	40,511	45.1%
Gross profit	\$ 25,897	\$ 17,856	45.0%	\$ 70,495	\$ 47,691	47.8%

Product revenues for the three months ended September 30, 2007 increased \$13.1 million, or 39.5% from the same period in 2006. Product revenues for the nine months ended September 30, 2007 increased \$41.1 million, or 46.6% from the same period in 2006. The increase in product revenue for the three and nine months ended September 30, 2007 was primarily due to increased unit volume of sales of medication and supply automation systems and central pharmacy products to new customers and secondarily from additional unit volume sales across our entire product line to existing customers.

Cost of product revenues for the three months ended September 30, 2007 increased by \$5.1 million, or 33.1% from the same period in 2006. This increase was primarily due to a \$3.8 million increase in direct material cost and manufacturing costs associated with increasing volume unit sales and with changes in our product mix and a \$1.4 million increase in labor costs, including a \$0.1 million increase in share-based compensation charges associated with SFAS No. 123(R). Cost of product revenues for the nine months ended September 30, 2007 increased by \$18.3 million, or 45.1% from the same period in 2006. This increase was primarily due to a \$12.4 million increase in direct material cost and manufacturing costs associated with increasing volume unit sales and with changes in our product mix, a \$4.2 million increase in labor costs, including a \$0.1 million increase in share-based compensation charges associated with SFAS No. 123(R), and a \$1.5 million increase in support expenses. The increase in support cost was largely due to infrastructure allocations driven by a faster increase of headcount in product costs than in operating expenses. Gross profit on product revenues for the three months ended September 30, 2007 increased \$8.0 million, or 45.0% from the same period in 2006. Gross profit on product revenues for the nine months ended September 30, 2007 increased \$22.8 million, or 47.8% from the same period in 2006. The absolute dollar increase of gross profit for the three and nine months ended September 30, 2007 was primarily as a result of higher product revenues.

Service and Other Revenues and Gross Profit

Edgar Filing: OMNICELL, Inc - Form 10-Q

The table below shows our service and other revenues, cost of service and other revenues and gross profit for the three and nine months ended September 30, 2007 and 2006 and the percentage change between those periods:

	Three Months Ended September 30,			Nine Months Ended September 30,		
	2007	2006	% Change	2007	2006	% Change
	(in thousands)			(in thousands)		
Service and other revenues	\$ 8,776	\$ 7,992	9.8%	\$ 25,864	\$ 23,422	10.4%
Cost of service and other revenues	4,860	3,317	46.5%	13,955	9,714	43.7%
Gross profit	\$ 3,916	\$ 4,675	(16.2)%	\$ 11,909	\$ 13,708	(13.1)%

Service and other revenues include revenues from service and maintenance contracts and month-to-month lease revenue from rentals of automation systems. Service and other revenues for the three months ended September 30, 2007 increased by \$0.8 million, or 9.8% from the same period in 2006. Service and other revenues for the nine months ended September 30, 2007 increased by \$2.4 million, or 10.4% from the same period in 2006. This increase was primarily due to the expansion of our installed base of automation systems and a resulting increase in number of customer support service contracts.

Cost of service and other revenues for the three months ended September 30, 2007 increased by \$1.5 million, or 46.5% from the same period in 2006. The increase was primarily due to \$0.8 million increase in labor costs in support of the expanded service base, and a \$0.6 million increase in support costs. The increase in support cost includes an increase of \$0.4 million in infrastructure allocations driven by a faster increase of headcount in service costs than in operating expenses. Cost of service and other revenues for the nine months ended September 30, 2007 increased by \$4.2 million, or 43.7% from the same period in 2006. The increase was primarily due to a \$2.0 million increase in labor costs in support of the expanded service base, a \$0.4 million increase in service spares and parts resulting from the expansion of our inventories to continue offering superior support to our customers, and a \$1.8 million increase in support costs. The increase in support cost includes an increase of \$1.0 million in infrastructure allocations driven by a faster increase of headcount in service costs than in operating expenses. Gross profit on service and other revenues for the three months ended September 30, 2007 decreased \$0.8 million, or 16.2% from the same period in 2006. Gross profit on service and other revenues for the nine months ended

September 30, 2007 decreased \$1.8 million, or 13.1% from the same period in 2006. This decrease in gross profit on service and other revenues for the three and nine months ended September 30, 2007 was primarily due to higher costs associated with the expansion of our installed base, improving our customer responsiveness and a larger allocation of shared operating expenses.

Operating Expenses

Edgar Filing: OMNICELL, Inc - Form 10-Q

	Three Months Ended September 30,			Nine Months Ended September 30,		
	2007	2006	% Change	2007	2006	% Change
	(in thousands)			(in thousands)		
Research and development	\$ 3,848	\$ 2,878	33.7%	\$ 10,999	\$ 7,858	40.0%
Selling, general and administrative	20,732	16,736	23.9%	58,497	48,031	21.8%
Total operating expenses	\$ 24,580	\$ 19,614	25.3%	\$ 69,496	\$ 55,889	24.3%

Research and Development. Research and development expenses for the three months ended September 30, 2007 increased by \$1.0 million, or 33.7% from the same period in 2006. Research and development expenses remained flat as a percentage of total revenues, representing 7.0% and 7.0% of total revenues for the three months ended September 30, 2007 and 2006, respectively. Research and development expenses for the nine months ended September 30, 2007 increased by \$3.1 million, or 40.0% from the same period in 2006. Research and development expenses increased as a percentage of total revenues, representing 7.1% and 7.0% of total revenues for the nine months ended September 30, 2007 and 2006, respectively. The increase in research and development expenses was due mainly to a \$0.9 million and \$2.7 million increase in labor and related expenses in the three and nine months ended September 30, 2007, respectively compared to the same period in 2006. The increase in research and development expenses was based on an increase in headcount. We expect research and development expenses to grow due to planned additional spending to improve and enhance our existing technologies and to create new technologies in health care automation.

Selling, General and Administrative. Selling, general and administrative expenses for the three months ended September 30, 2007 increased by \$4.0 million, or 23.9% from the same period in 2006. Selling, general and administrative expenses declined as a percentage of total revenues, representing 37.6% and 40.6% of total revenues for the three months ended September 30, 2007 and 2006, respectively. Selling, general and administrative expenses for the nine months ended September 30, 2007 increased by \$10.5 million, or 21.8% from the same period in 2006. Selling, general and administrative expenses declined as a percentage of total revenues, representing 37.7% and 43.0% of total revenues for the nine months ended September 30, 2007 and 2006, respectively.

In the three months ended September 30, 2007, the increase in selling, general and administrative expenses was primarily due to a \$3.1 million increase in labor costs, including a \$0.3 million increase in share-based compensation charges associated with SFAS No. 123(R) and a \$0.3 million increase in finder's fees from group purchasing organizations, due to higher sales volume. In the nine months ended September 30, 2007, the increase in selling, general and administrative expenses was primarily due to a \$9.3 million increase in labor costs, including a \$0.6 million increase in share-based compensation charges associated with SFAS No. 123(R) and a \$1.0 million increase in finder's fees from group purchasing organizations, due to higher sales volume. These increases were partially offset by a \$0.4 million decrease in seasonal advertising expenses. We expect selling, general and administrative expenses to continue to grow in absolute dollars as we continue to add headcount to support a greater unit volume of customer sales and installation of customer orders. The decrease of selling, general and administrative expenses as a percentage of sales for the nine month period ended September 30, 2007 compared to the same period in 2006 was primarily due to a higher allocation of shared operating expenses to cost of sales, together with increased efficiencies in both sales and administrative functions as sales volumes have grown. We expect further, yet more modest efficiency benefits as sales continue to grow and once infrastructure investments are complete.

Interest Income

The increase in interest income for the three and nine months ended September 30, 2007 over the comparable periods in 2006 was primarily due to higher average cash and cash equivalents balances as a result of the \$90.2 million in net cash proceeds from our public offering of common stock in May 2007 and the impact of higher interest rates in 2007 as compared to 2006.

Edgar Filing: OMNICELL, Inc - Form 10-Q

	Three Months Ended September 30,			Nine Months Ended September 30,		
	2007	2006	% Change	2007	2006	% Change
Interest Income	(in thousands)			(in thousands)		
\$	2,071	\$ 600	245.2%	\$ 4,137	\$ 1,323	212.7%

(Benefit from) Provision for Income Taxes

Edgar Filing: OMNICELL, Inc - Form 10-Q

Comparison of the three and nine months ended September 30, 2007 and 2006, (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2007	2006	2007	2006
(Benefit from) provision for income taxes	\$ 347	\$ 384	\$ (12,015)	\$ 522

The tax provision for the three months ended September 30, 2007 consisted of taxes due on minimum and alternative minimum federal and state taxes and resolution of certain FIN 48 tax exposures. The tax benefit for nine months ended September 30, 2007 consisted of the partial release of a valuation allowance carried on deferred tax assets, offset by taxes due on minimum and alternative minimum federal and state taxes and resolution of certain FIN 48 tax exposures. The income tax provision for the three months and nine months ended September 30, 2006 consisted of both federal and state alternative minimum and other state taxes. Alternative minimum taxes apply due to utilization of net operating loss carry forwards which reduce our tax liabilities to minimum amounts. For the three and nine months ended September 30, 2006, there was no tax impact relating to the valuation allowance carried on deferred tax assets.

We believe there is a risk associated with our ability to utilize net operating losses, or NOLs, and have retained a valuation allowance of \$24.9 million offsetting net deferred tax assets as of September 30, 2007. Statement of Financial Accounting Standards No. 109,

Accounting for Income Taxes, or SFAS No. 109, requires us to evaluate the realization of our deferred tax assets. Circumstances leading to a change in judgment about our deferred tax assets included a secondary stock offering in May 2007 which provided funding for additional growth opportunities, utilization of NOLs, recent cumulative history of profitability and a favorable near term business forecast. These items, taken collectively lead us to believe a portion of our deferred tax assets will be realized. The remaining portion of the deferred tax assets will remain subject to a valuation allowance until future circumstances indicate they may be realized. The remaining deferred tax assets subject to a valuation allowance include temporary book-tax differences and NOLs related to stock options. The NOLs are approximately \$9.9 million and the valuation allowance will be released when the NOLs are utilized to reduce cash taxes and an associated benefit will be an offset to additional paid-in capital. Approximately \$2.2 million of operating losses are fully offset by a valuation allowance due to limitations imposed by Internal Revenue Code 382.

Product Backlog

Product backlog is the dollar value of medication and supply dispensing systems that have shipped to customers but are not yet installed at the customer site, plus the dollar value of such systems that have not shipped but for which we have purchase orders and which we believe we will install and bill within one year. We expect our product backlog will continue to grow over time. At September 30, 2007, our product backlog was \$140.6 million, a \$41.6 million or 42% increase from the comparable period in 2006, and a \$26.3 million or 23% increase from December 31, 2006.

We intend to maintain a product backlog at levels consistent with our customers' product installation cycles. We recently announced that we will disclose product backlog amounts annually following our fiscal year end.

Liquidity Sources, Requirements and Contractual Cash Commitments

At September 30, 2007, we had working capital of \$208.8 million. Our principal sources of liquidity as of September 30, 2007 consisted of \$175.5 million in cash and cash equivalents.

In May 2007, we closed the sale and issuance of 4,485,000 shares of our common stock to the public at a price of \$21.50 per share. The sale of our common stock yielded proceeds of approximately \$90.2 million, net of underwriting discounts and offering expenses. We intend to apply the net proceeds towards potential licenses and acquisitions of complementary technologies, products and companies, general corporate purposes and working capital.

Operating Activities. Operating activities provided \$16.2 million of cash for the nine months ended September 30, 2007, compared to \$10.4 million of cash provided during the same period in 2006. This increase in cash provided by operating activities was due to higher operating income resulting from our increased sales volume and interest income earned. More specifically, contributors to the increase of cash from operations in the nine months ended September 30, 2007 were net income of \$29.0 million, non-cash adjustments to income for depreciation and amortization of \$2.7 million, \$8.0 million of share-based compensation expense due to SFAS No. 123(R), a \$1.4 million provision for excess and obsolete inventories and \$12.8 million relating to the partial release of a valuation allowance carried on deferred tax assets, as well as

increases of \$2.7 million in other current assets, \$1.3 million in deferred gross profit and \$7.2 million in deferred service revenue. These amounts were offset by decreases of \$8.1 million in advance customer payments, \$13.3 million in accounts receivable and \$3.6 million in other non-current assets.

Investing Activities. We used \$5.0 million for investing activities during the nine months ended September 30, 2007, compared to \$2.7 million during the same period in 2006. Cash used in investing activities was higher in the first nine months of 2007 than in the same period in 2006 primarily due to investments in information technology infrastructure and leasehold improvements associated with additional rented office space, offset by lower use of cash related to intellectual property acquisitions.

Financing Activities. Net cash provided by financing activities totaled \$103.7 million for the nine months of 2007, of which \$13.5 million was provided by the sale of common stock through our stock option and employee stock purchase plans and approximately \$90.2 million of net proceeds from the sale and issuance of 4,485,000 shares of our common stock to the public. Net cash provided by financing activities was \$12.9 million for the same period in 2006 and was provided by the sale of common stock through our stock option and employee stock purchase plans.

Since the close of our public offering in May 2007, we have not used the proceeds from the offering, but it is still our intention to use the funds for potential future licenses and acquisitions of complimentary technologies, products and companies, general corporate purposes and working capital. Our operating expenses and cost of providing services may increase as a result of the need to hire additional personnel to support our continued sales growth and marketing efforts. We plan to fund our short-term operations from our current cash balances and cash generated from operations.

As of September 30, 2007, we had \$7.4 million in contractual commitments to third parties for non-cancelable operating leases, commitments to contract manufacturers and suppliers and other purchase commitments. See Note 11, Commitments and Contingencies, to our condensed consolidated financial statements included in this Quarterly Report for further information with respect to these commitments.

We believe our current cash balances and cash flows generated by operations will be sufficient to satisfy our anticipated cash needs for working capital and capital expenditures through at least the next 12 months.

At September 30, 2007, we had no off-balance sheet arrangements as defined in Regulation S-K 303(a)(4)(ii).

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Edgar Filing: OMNICELL, Inc - Form 10-Q

We hold our assets primarily in cash and cash equivalents in instruments with terms of less than 90 days, such as short-term marketable debt securities, money market funds and other cash equivalents. As a result, if market interest rates were to increase immediately and uniformly by 10% from levels at September 30, 2007, the fair value of cash and cash equivalents would not change by a material amount.

Our activities give rise to market risk representing the potential loss in the fair value of assets caused by future movements in interest rates. We are exposed to interest rate risk arising from changes in interest rates related to components of our product backlog composed of offers to non-U.S. Government customers for multi-year, non-cancelable payment terms. Generally we sell non-U.S. Government receivables to third-party leasing finance companies, and we reflect the financing interest expense on the sale of these receivables as a component of our revenue. We record our revenue at the net present value of the multi-year payment stream using the contractual interest rate charged us by the third-party leasing company. As interest rates rise, the level of future revenue associated with these orders may fall.

Sensitivity Analysis

Edgar Filing: OMNICELL, Inc - Form 10-Q

We performed a sensitivity analysis assuming a hypothetical 10% adverse movement in interest rates from actual year-end interest rates related to underlying exposure of product backlog as described in the paragraph above. As of September 30, 2007 and December 31, 2006 the analysis indicated that this hypothetical market movements would have an adverse effect of approximately \$0.3 million and \$0.5 million, respectively, on our condensed consolidated results of operations.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended) as of September 30, 2007. Based on such evaluation, our chief executive officer and chief financial officer have concluded that our efforts to remediate the material weakness described below and identified by the same evaluation conducted at December 31, 2006 and set forth in our Annual Report on Form 10-K for the year ended December 31, 2006 were not yet completed, and therefore our disclosure controls and procedures as of September 30, 2007 were not effective to ensure that the information required to be disclosed by us in the reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and instructions for such reports.

Changes in Internal Control over Financial Reporting

Edgar Filing: OMNICELL, Inc - Form 10-Q

In the year ended December 31, 2006, we identified one material weakness in our internal control over financial reporting as of that date, related to our financial statement close process. Controls pertaining to the timely review of reconciliations and account balances performed during the preparation of financial statements were not effective, impacting a number of accounts including lease receivables, prepaid and other current assets, inventories, accrued liabilities, product revenue and share-based compensation. The largest error was interest income associated with leases, resulting in a revision of quarterly financial data for 2006. The adjustments associated with these errors were recorded in the consolidated financial statements for the year ended December 31, 2006 filed with the SEC on March 23, 2007. We have implemented the following remediation actions designed to address this material weakness: a) added additional reconciliations and recalculations of lease receivable data; b) continued to strengthen personnel through training of existing staff and hiring additional qualified personnel; c) defined roles and responsibilities throughout the accounting/finance organization; and d) improved processes and procedures to ensure timely reconciliations of all major balance sheet items. We will continue to perform the enhanced procedures as part of our normal closing process.

As of September 30, 2007, our remediation efforts related to the material weakness which existed as of December 31, 2006 are substantially complete; however, we and our independent registered public accounting firm have not completed testing of the enhanced internal controls over financial reporting. Our efforts to remediate and test controls surrounding the material weakness will continue during fiscal 2007.

Notwithstanding the above-mentioned material weakness, we believe that the condensed consolidated financial statements included in this report fairly represent our consolidated position as of, and condensed consolidated results of operations for the nine months ended September 30, 2007.

There were no other changes in internal control over financial reporting in the quarter ended September 30, 2007 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

Edgar Filing: OMNICELL, Inc - Form 10-Q

On February 20, 2007, we were served with the third amended petition in a lawsuit entitled Alcala, et al. v. Cardinal Health, Inc., et al., case number 2006 09-4487-G, which named us as a defendant. This lawsuit was filed in the District Court of Cameron County, Texas. The lawsuit alleges claims against us for strict products liability, negligence and gross negligence arising from the use of our product by defendant Cardinal Health 109, Inc. in connection with the treatment of a patient who died after receiving treatment. The petition, which was filed by the family and estate of the deceased patient, alleges that defects in the design of our product contributed to the patient's death which was allegedly caused by the administration of the wrong medication. We deny any liability, have engaged our insurance carrier on this matter and intend to vigorously defend against these claims.

Item 1A. RISK FACTORS

Edgar Filing: OMNICELL, Inc - Form 10-Q

We have identified the following risks and uncertainties that may have a material adverse effect on our business, financial condition or results of operations. Our business faces significant risks and the risks described below may not be the only risks we face. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations. If any of these risks occur, our business, results of operations or financial condition could suffer and the market price of our common stock could decline. We have marked with an asterisk (*) those risk factors below that reflect substantive changes from the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2006, filed with the Securities and Exchange Commission on March 23, 2007.

The medication management and supply chain solutions market is highly competitive and we may be unable to compete successfully against new entrants and established companies with greater resources.

The medication management and supply chain solutions market is intensely competitive and is characterized by evolving technologies and industry standards, frequent new product introductions and dynamic customer requirements. We expect continued and increased competition from current and future competitors, many of which have significantly greater financial, technical, marketing and other resources than we do. Our current direct competitors in the medication management and supply chain solutions market include Pyxis Corporation (a division of Cardinal Health, Inc.), McKesson Automation Inc. (a business unit of McKesson Corporation), AmerisourceBergen Corporation (through its acquisition of MedSelect, Inc. and Automed), the Baxter Medication Delivery business of Baxter International Inc., Cerner Corporation, Eclipsys Corporation, IDX Systems Corporation (a division of GE Healthcare) and Siemens Medical Solutions (a division of Siemens AG).

The competitive challenges we face in the medication management and supply chain solutions market include, but are not limited to, the following:

our competitors may develop, license or incorporate new or emerging technologies or devote greater resources to the development, promotion and sale of their products and services;

certain competitors have greater brand name recognition and a more extensive installed base of medication and supply dispensing systems or other products and services than we do, and such advantages could be used to increase their market share;

other established or emerging companies may enter the medication management and supply chain solutions market;

current and potential competitors may make strategic acquisitions or establish cooperative relationships among themselves or with third parties, including larger, more established healthcare supply companies, thereby increasing their ability to develop and offer products and services to address the needs of our prospective customers; and

our competitors may secure products and services from suppliers on more favorable terms or secure exclusive arrangements with suppliers or buyers that may impede the sales of our products and services.

Competitive pressures could result in price reductions of our products and services, fewer customer orders and reduced gross margins, any of which could harm our business.

Changing customer requirements could decrease the demand for our products and services.

The medication management and supply chain solutions market is intensely competitive and is characterized by evolving technologies and industry standards, frequent new product introductions and dynamic customer requirements that may render existing products obsolete or less competitive. As a result, our position in the medication management and supply chain solutions market could erode rapidly due to unforeseen changes in the features and functions of competing products, as well as the pricing models for such products. Our future success will depend in part upon our ability to enhance our existing products and services and to develop and introduce new products and services to meet changing customer requirements. The process of developing products and services such as those we offer is extremely complex and is expected to become increasingly more complex and expensive in the future as new technologies are introduced. If we are unable to enhance our existing products or develop new products to meet changing customer requirements, demand for our products could decrease.

Any reduction in the demand for or adoption of our medication and supply dispensing systems and related services would reduce our revenues.

Our medication and supply dispensing systems represent only one approach to managing the distribution of pharmaceuticals and supplies at healthcare facilities. Many healthcare facilities still use traditional approaches that do not include automated methods of medication and supply dispensing management. As a result, we must continuously educate existing and prospective customers about the advantages of our products. Our medication and supply dispensing systems typically represent a sizeable initial capital expenditure for healthcare organizations. Changes in the budgets of these organizations and the timing of spending under these budgets can have a significant

effect on the demand for our medication and supply dispensing systems and related services. In addition, these budgets are often characterized by limited resources and conflicting spending priorities among different departments. Any decrease in expenditures by these healthcare facilities, particularly our significant customers, could decrease demand for our medication and supply dispensing systems and related services and reduce our revenues. We may not continue to be successful in marketing our medication and supply dispensing systems, and the level of market acceptance of our systems may not continue to be sufficient to generate operating income.

Our current and potential customers may have other business relationships with our competitors and consider those relationships when deciding between our products and services and those of our competitors.

Many of our competitors are large drug and medical-surgical supply distribution companies that sell their distribution services to our current and potential customers. As a result, if a customer is a distribution customer of one of our competitors, the customer may be motivated to purchase medication and supply dispensing systems or other automation solutions from our competitor in order to maintain or enhance their business relationship with that competitor.

If we experience delays in or loss of sales of, delays in installations of, or delays in the recognition of revenue associated with our medication and supply dispensing systems, our competitive position, results of operations and financial condition could be harmed.

The purchase of our medication and supply dispensing systems is often part of a customer's larger initiative to re-engineer its pharmacy, distribution and materials management systems. As a result, the purchase of our medication and supply dispensing systems often entail larger strategic purchases by customers that frequently require more complex and stringent contractual requirements and generally involves a significant commitment of management attention and resources by prospective customers. These larger and more complex transactions often require the input and approval of many decision-makers, including pharmacy directors, materials managers, nurse managers, financial managers, information systems managers, administrators, lawyers and boards of directors. For these and other reasons, the sales cycle associated with the sale of our medication and supply dispensing systems is often lengthy and subject to a number of delays over which we have little or no control. A delay in, or loss of, sales of our medication and supply dispensing systems could cause our operating results to vary significantly from quarter to quarter and could harm our business.

In addition, and in part as a result of the complexities inherent in larger transactions, the average time between the purchase and installation of our systems has increased for reasons that are often outside of our control. Since we recognize revenue only upon installation of our systems at a customer's site, any delay in installation by our customers also causes a delay in the recognition of revenue for that system. Further, the larger, more complex transactions often require us to include negotiated contractual terms that have the effect of delaying revenue recognition under the accounting rules that apply to us.

We have experienced substantial growth and we cannot assure you that we will be able to manage future growth.*

Our revenue grew by 27.3% in fiscal 2006 compared to fiscal 2005, and 33.8% and 39.0% in the three and nine months ended September 30, 2007 compared to the same period in 2006. Our ability to continue to grow future revenues profitably is dependent on our ability to continue to manage costs and control expenses. We expect our revenues to continue to grow, and we may not be able to manage this anticipated growth effectively. Management of our anticipated growth will require the devotion of significant time and attention.

Our revenue growth is dependent on our ability to continue to receive orders from customers, the volume of installations we are able to complete, our ability to continue to meet our customers needs and provide a quality installation experience, and our flexibility in manpower allocations among customers to complete installations on a timely basis. Our revenue growth rate may slow in the future if our revenues increase to higher levels.

Our expense control is dependent on our ability to continue to develop and leverage effective and efficient human and information technology systems, our ability to gain efficiencies in our workforce through the local and worldwide labor markets, and our ability to grow our outsourced vendor supply model. Our expense growth rate may equal or exceed our revenue growth rate if we are unable to streamline our operations, or fail to reduce the costs or increase the margins of our products.

If we are unable to recruit and retain skilled and motivated personnel, our competitive position, results of operations and financial condition could be harmed.

Our success is highly dependent upon the continuing contributions of our key management, sales, technical and engineering staff. We believe that our future success will depend upon our ability to attract, train and retain highly skilled and motivated personnel. As more of our products are installed in increasingly complex environments, greater technical expertise will be required. As our installed base of customers increases, we will also face additional demands on our customer service and support personnel, requiring additional resources to meet these demands. We may experience difficulty in recruiting qualified personnel. Competition for qualified technical, engineering, managerial, sales, marketing, financial reporting and other personnel can be intense and we cannot assure you that we will be successful in attracting and retaining qualified personnel. Competitors have in the past attempted, and may in the future attempt, to recruit our employees.

In addition, we have historically used stock options and other forms of equity compensation as key components of our employee compensation program in order to align employees' interests with the interests of our stockholders, encourage employee retention and provide competitive compensation packages. Share-based compensation expense recorded under SFAS No. 123(R) could make it more difficult and less favorable for us to grant stock options to employees in the future. If employees believe that the incentives that they would receive under any such modified strategy are less attractive, we may find it difficult to attract, retain and motivate employees. Failure to attract and retain key personnel could harm our competitive position, results of operations and financial condition.

We may not be able to successfully integrate acquired businesses or technologies into our existing business, which could negatively impact our operating results.

As a part of our business strategy, during the past few years we acquired an automated pharmacy storage and retrieval system, a bedside dispensing platform, and an open supply management system. We may seek to acquire other businesses, technologies or products in the future. We cannot assure you that any transaction we complete will result in long-term benefits to us or our stockholders, or that our management will be able to integrate or manage the acquired business effectively. Acquisitions entail numerous risks, including difficulties associated with the integration of operations, technologies, products and personnel that, if realized, could harm our operating results. Risks related to potential acquisitions include, but are not limited to:

difficulties in combining previously separate businesses into a single unit;

substantial diversion of management's attention from day-to-day business when evaluating and negotiating such transactions and then integrating an acquired business;

discovery, after completion of the acquisition, of liabilities assumed from the acquired business or of assets acquired that are not realizable;

failure to achieve anticipated benefits such as cost savings and revenue enhancements;

difficulties related to assimilating the products of an acquired business; and

failure to understand and compete effectively in markets in which we have limited previous experience.

The healthcare industry faces financial constraints and consolidation that could adversely affect the demand for our products and services.

The healthcare industry has faced, and will likely continue to face, significant financial constraints. For example, the shift to managed care in the 1990s put pressure on healthcare organizations to reduce costs, and the Balanced Budget Act of 1997 significantly reduced Medicare reimbursement to healthcare organizations. Our automation solutions often involve a significant financial commitment by our customers and, as a result, our ability to grow our business is largely dependent on our customers' information technology budgets. To the extent healthcare information technology spending declines or increases more slowly than we anticipate, demand for our products and services could decline.

Edgar Filing: OMNICELL, Inc - Form 10-Q

Many healthcare providers have consolidated to create larger healthcare delivery organizations with greater market power. If this consolidation continues, it could reduce the number of our target customers. In addition, the resulting organizations could have greater bargaining power, which may lead to price erosion.

If we are unable to maintain our relationships with group purchasing organizations or other similar organizations, we may have difficulty selling our products and services.

We have contracts with various group purchasing organizations, such as AmeriNet, Inc., Consorta, Inc., HealthTrust Purchasing Group, L.P., MAGNET Group, Novation, LLC, and Premier, Inc., which enable us to more readily sell our products and services to customers represented by these organizations. Our contracts with these organizations are terminable at the convenience of either party. The loss of any of these relationships could impact the breadth of our customer base and could impair our ability to increase our revenues. We cannot assure you that these organizations will renew our contracts on similar terms, if at all, and they may choose to terminate our contracts before they expire.

Our quarterly operating results may fluctuate and may cause our stock price to decline.

Our quarterly operating results may vary in the future depending on many factors that include, but are not limited to, the following:

the ability to successfully install our products on a timely basis and meet other contractual obligations necessary to recognize revenue;

the size and timing of orders for our medication and supply dispensing systems, and their installation and integration; the overall demand for healthcare medication management and supply chain solutions;

changes in pricing policies by us or our competitors;

the number, timing and significance of product enhancements and new product announcements by us or our competitors;

the relative proportions of revenues we derive from products and services;

our customers' budget cycles;

changes in our operating expenses;

the performance of our products; changes in our business strategy; and

economic and political conditions, including fluctuations in interest rates and tax increases.

Due to all of these factors, our quarterly revenues and operating results are difficult to predict and may fluctuate, which in turn may cause the market price of our stock to decline.

If the market price of our common stock continues to be highly volatile, the value of your investment in our common stock may decline.*

During the nine month period ended September 30, 2007, our common stock traded between \$16.52 and \$28.54 per share. The market price for shares of our common stock has been and may continue to be highly volatile. In addition, our announcements or external events may have a significant impact on the market price of our common stock. These announcements or external events may include:

changes in our operating results;

developments in our relationships with corporate customers;

changes in the ratings of our common stock by securities analysts;

announcements by us or our competitors of technological innovations or new products; or

general economic and market conditions.

Furthermore, the stock market as a whole from time to time has experienced extreme price and volume fluctuations, which have particularly affected the market prices for technology companies. These broad market fluctuations may cause the market price of our common stock to decline irrespective of our performance. In addition, sales of substantial amounts of our common stock in the public market could lower the market price of our common stock.

We have outstanding options that have the potential to dilute shareholder value and cause our stock price to decline.*

We frequently grant stock options to our employees. At September 30, 2007, we had options outstanding to purchase approximately 4.8 million shares of our common stock at exercise prices ranging from \$1.80 to \$20.95 per share. If some or all of these shares are sold into the public market over a short time period, the price of our common stock may decline, as the market may not be able to absorb those shares at the prevailing market prices. Such sales may also make it more difficult for us to sell equity securities in the future on terms that we deem acceptable.

Beginning with fiscal 2006, we recognized expense for share-based compensation related to employee stock options and employee stock purchases. We cannot assure you that the expense we are required to recognize measures the accurate value of our share-based payment awards, and the recognition of this expense could cause the trading price of our common stock to decline.

On January 1, 2006, we adopted SFAS No. 123(R), which requires the measurement and recognition of compensation expense for all share-based compensation based on estimated fair values. As a result, starting with fiscal 2006, our operating results contain a charge for share-based compensation expense related to employee stock options and employee stock purchases. The application of SFAS No. 123(R) requires the use of an option-pricing model to determine the fair value of share-based payment awards. This determination of fair value is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behavior.

As a result of the adoption of SFAS No. 123(R), beginning with fiscal 2006, our earnings were lower than they would have been had we not been required to adopt SFAS No. 123(R). This will continue to be the case for future periods. We cannot predict the effect that this adverse impact on our reported operating results will have on the trading price of our common stock.

Our internal control over financial reporting and our disclosure controls and procedures were not effective as of December 31, 2006. Our failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could cause our stock price to decline.*

Section 404 of the Sarbanes-Oxley Act of 2002 and the related rules and regulations of the SEC require annual management assessments of the effectiveness of our internal control over financial reporting and a report by our independent registered public accounting firm attesting to and reporting on these assessments. If we fail to maintain effective internal control over financial reporting, as such standards are modified, supplemented or amended from time to time, we may not be able to conclude that we have effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 and the related rules and regulations of the SEC. For example, for the fiscal year ended December 31, 2006, we determined that controls pertaining to the timely review of reconciliations and account balances impacting lease receivables, prepaid and other current assets, inventories, accrued liabilities, product revenue and share-based compensation were not effective. The largest error was a misstatement of interest income associated with leases, resulting in a revision of quarterly financial data in 2006. As a result, our management concluded that our internal control over financial reporting and our disclosure controls and procedures were not effective as of December 31, 2006. As of September 30, 2007, our remediation efforts related to the material weakness which existed as of December 31, 2006 are substantially complete, but we and our independent registered public accounting firm have not yet completed testing of the enhanced internal controls over financial reporting. If, upon testing, we find such remediation efforts have not been effective, or if we cannot in the future favorably assess, or our independent registered public accounting firm is unable to provide an unqualified attestation report on our assessment of, the effectiveness of our internal control over financial reporting, investors may lose confidence in the reliability of our financial reports, which could cause our stock price to decline.

If our U.S. government customers do not receive their annual funding, our ability to recognize revenues on future sales to U.S. government customers, to sell our U.S. government receivables to third-party leasing companies or to collect payments on unsold receivables from U.S. government customers could be impaired.*

U.S. government customers sign contracts with five-year non-cancelable payment terms but are subject to one-year government budget funding cycles. In our judgment and based on our history with these accounts, we believe these receivables are collectable. However, in the future, the failure of any of our U.S. government customers to receive their annual funding could impair our ability to sell to these customers or to sell our U.S. government receivables to third-party leasing companies. In addition, the ability to collect payments on unsold receivables could be impaired and may result in a write-down of our unsold receivables to U.S. government customers. As of September 30, 2007, the balance of our unsold leases to U.S. government customers was \$14.6 million.

We depend on a limited number of suppliers for our medication and supply dispensing systems and our business may suffer if we are unable to obtain an adequate supply of components and equipment on a timely basis.

Although we generally use parts and components for our products with a high degree of modularity, certain components are presently available only from a single source or limited sources. We have generally been able to obtain adequate supplies of all components in a timely manner from existing sources, or where necessary, from alternative sources of supply. In 2006 and 2007, we secured multiple single source third-party manufacturers to build several of our sub-assemblies. Our failure to obtain alternative vendors, if required, for any of the numerous components used to manufacture our products could limit our ability to manufacture our products and harm our business. Our reliance on a few single source partners to build our hardware sub-assemblies, a reduction or interruption in supply from our partners or suppliers, or a significant increase in the price of one or more components could have an adverse impact on our business, operating results and financial condition. In addition, this impact could damage customer relationships and any failure of a contractor to perform adequately could harm our business.

If we fail to manage our inventory properly, our revenue, gross margin and profitability could suffer.

Managing our inventory of components and finished products is a complex task. A number of factors, including, but not limited to, the need to maintain a significant inventory of certain components that are in short supply or that must be purchased in bulk to obtain favorable pricing, the general unpredictability of demand for specific products and customer requests for quick delivery schedules, may result in us maintaining large amounts of inventory. Other factors, including changes in market demand, customer requirements and technology, may cause inventory to become obsolete. Any excess or obsolete inventory could result in inventory write-downs, which in turn could harm our business and results of operations.

If we are unable to successfully integrate our automation solutions with the existing information systems of our customers, they may choose not to use our products and services.

For healthcare facilities to fully benefit from our automation solutions, our systems must integrate with their existing information systems. This may require substantial cooperation, investment and coordination on the part of our customers. There is little uniformity in the systems currently used by our customers, which complicates the integration process. If these systems are not successfully integrated, our customers could choose not to use or to reduce their use of our automation solutions, which would harm our business.

Our failure to protect our intellectual property rights could negatively affect our ability to compete.

Our success depends in part on our ability to obtain patent protection for technology and processes and our ability to preserve our trademarks, copyrights and trade secrets. We have pursued patent protection in the United States and foreign jurisdictions for technology that we believe to be proprietary and for technology that offers us a potential competitive advantage for our products. We intend to continue to pursue such protection in the future. Our issued patents relate to various features of our medication and supply dispensing systems. We cannot assure you that we will file any patent applications in the future, that any of our patent applications will result in issued patents or that, if issued, such patents will provide significant protection for our technology and processes. Furthermore, we cannot assure you that others will not develop technologies that are similar or superior to our technology or that others will not design around the patents we own. All of our system software is copyrighted and subject to the protection of applicable copyright laws. Despite our efforts to protect our proprietary rights, unauthorized parties may attempt to copy aspects of our products or obtain and use information that we regard as proprietary.

Intellectual property claims against us could harm our competitive position, results of operations and financial condition.

We are aware of one third-party patent issued several years ago that may relate to certain of our products. Although we have received no notice alleging infringement from this third-party to date, there can be no assurance that such third party will not assert an infringement claim against us in the future. Other than this patent, we do not believe that any of our products infringe upon the proprietary rights of any third parties. In the future, third parties may claim that we have infringed upon their intellectual property rights with respect to current or future products. We expect that developers of medication and supply dispensing systems will be increasingly subject to infringement claims as the number of products and competitors in our industry grows and the functionality of products in different industry segments overlaps. We do not carry special insurance that covers intellectual property infringement claims; however, such claims may be covered under our traditional insurance policies. These policies contain terms, conditions and exclusions that make recovery for intellectual infringement claims difficult to guarantee. Any infringement claims, with or without merit, could be time-consuming to defend, result in costly litigation, divert management's attention and resources, cause product shipment delays or require us to enter into royalty or licensing agreements. These royalty or licensing agreements, if required, may not be available on terms acceptable to us, or at all, which could harm our competitive position, results of operations and financial condition.

Our software products are complex and may contain defects, which could harm our reputation, results of operations and financial condition.

We market software products. These software products include OmniLinkRx, SecureVault, OmniRx, OptiFlex, SafetyMed, OmniBuyer and OmniGate. Although we perform extensive testing prior to releasing software products, these products may contain undetected errors or bugs when first released. These may not be discovered until the product has been used by customers in different application environments. Failure to discover product deficiencies or bugs could delay product introductions, require design modifications to previously shipped products, cause unfavorable publicity or negatively impact system shipments, any of which could harm our business, financial condition and results of operations.

Product liability claims against us could harm our competitive position, results of operations and financial condition.

Our products provide medication management and supply chain solutions for the healthcare industry. Despite the presence of healthcare professionals as intermediaries between our products and patients, if our products fail to provide accurate and timely information or operate as designed, customers, patients or their family members could assert claims against us for product liability. Moreover, failure of health care facility employees to use our products for their intended purposes could result in product liability claims against us. For example, in February 2007, we were named as a defendant in a lawsuit filed by the family and estate of a deceased patient that alleges that defects in the design of one of our products contributed to the patient's death, which was allegedly caused by the administration of the wrong medication. Litigation with respect to liability claims, regardless of any outcome, could result in substantial cost to us, divert management's attention from operations and decrease market acceptance of our products. We possess a variety of insurance policies that include coverage for general commercial liability, technology errors and omissions liability. However, these policies may not be adequate against product liability claims. A successful claim brought against us, or any claim or product recall that results in negative publicity about us, could harm our competitive position, results of operations and financial condition. Also, in the event that any of our products are defective, we may be required to recall or redesign those products.

If our new product solutions do not achieve market acceptance, our sales and operating results will be affected.

We occasionally introduce new products. Our ability to achieve our business goals is dependent in part on customer acceptance of these new products. We cannot assure you that we will be successful in marketing these products, that these products will compete effectively with similar products sold by our competitors or that the level of market acceptance of such products will be sufficient to generate expected revenues and synergies with our other products.

Deployment of these new products often requires interoperability with other Omnicell products as well as with healthcare facilities' existing information management systems. If these products fail to satisfy these demanding technological objectives, our customers may be dissatisfied and we may be unable to generate future sales. Failure to establish a significant base of customer references will significantly reduce our ability to sell these products to additional customers.

We are dependent on technologies provided by third-party vendors.

Some of our products incorporate technologies owned by third parties that are licensed to us for use, modification, and distribution. If we lose access to third-party technologies, or we lose the ongoing rights to modify and distribute these technologies with our products we will either have to devote resources to independently develop, maintain and support the technologies ourselves or transition to another vendor. Any independent development, maintenance or support of these technologies by us or the transition to alternative technologies could be costly, time consuming and could delay our product releases and upgrade schedules. These factors could negatively and materially affect our ability to market, sell or distribute our products and in turn our business and prospects.

Our international operations may subject us to additional risks that can adversely affect our operating results.

We currently have operations outside of the United States, consisting primarily of software development and customer support through our India subsidiary. Our international operations subject us to a variety of risks, including:

the difficulty of managing an organization operating in various countries;

growing political sentiment against international outsourcing of support services and development;

reduced protection for intellectual property rights in some countries;

changes in regulatory requirements; the requirement to comply with a variety of international laws and regulations, including local labor ordinances and changes in tariff rates;

fluctuations in currency exchange rates and difficulties in transferring funds from certain countries; and

political unrest, terrorism and the potential for other hostilities in areas in which we have facilities.

Our success depends, in part, on our ability to anticipate and address these risks. We cannot assure you that these or other factors will not adversely affect our business or operating results.

Government regulation of the healthcare industry could reduce demand for our products.

While the manufacture and sale of our current products are not regulated by the United States Food and Drug Administration, or FDA, or the Drug Enforcement Administration, or DEA, these products, or our future products, if any, may be regulated in the future by these or other federal agencies due to future legislative and regulatory initiatives or reforms. Direct regulation of our business and products by FDA, DEA or other federal agencies could reduce the demand for our products and reduce our revenues. In addition, healthcare providers and facilities that use our equipment and dispense controlled substances are subject to regulation by DEA. The failure of these providers and facilities to comply with DEA requirements, including the Controlled Substances Act and its implementing regulations, could reduce demand for our products and harm our competitive position, results of operations and financial condition. Pharmacies are regulated by individual state boards of pharmacy that issue rules for pharmacy licensure in their respective jurisdictions. State boards of pharmacy do not license or approve our medication and supply dispensing systems; however, pharmacies using our equipment are subject to state board approval. The failure of such pharmacies to meet differing requirements from a significant number of state boards of pharmacy could decrease demand for our products and harm our competitive position, results of operations and financial condition. Similarly, hospitals must be accredited by the Joint Commission on Accreditation of Healthcare Organizations, or JCAHO, in order to be eligible for Medicaid and Medicare funds. JCAHO does not approve or accredit medication and supply dispensing systems; however, disapproval of our customers' medication and supply dispensing management methods and their failure to meet JCAHO requirements could decrease demand for our products and harm our competitive position, results of operations and financial condition.

While we have implemented a Privacy and Use of Information Policy and adhere to established privacy principles, use of customer information guidelines and related federal and state statutes, we cannot assure you that we will be in compliance with all federal and state healthcare information privacy and security laws that we are directly or indirectly subject to, including, without limitation, the Health Insurance Portability and Accountability Act of 1996, or HIPAA. Among other things, this legislation required the Secretary of Health and Human Services, or HHS, to adopt national standards governing the conduct of certain electronic health information transactions and

protecting the privacy and security of personally identifiable health information maintained or transmitted by covered entities, which include pharmacies and other healthcare providers with which we do business. The standards adopted to date include, among others, the Standards for Privacy of Individually Identifiable Health Information, which restrict the use and disclosure of personally identifiable health information by covered entities, and the Security Standards, which require covered entities to implement administrative, physical and technical safeguards to protect the integrity and security of certain electronic health information. While we are not directly regulated as a covered entity under HIPAA, we are a business associate to many of our customers that are covered entities. Many of these customers have required that we enter into written agreements governing the way we handle and safeguard any patient information we may encounter in providing our products and services and may impose liability on us for failure to meet our contractual obligations. A number of states have also enacted privacy and security statutes and regulations that, in some cases, are more stringent than HIPAA and may apply directly to us. If our past or present operations are found to violate any of these laws, we may be subject to fines, penalties and other sanctions. In addition, we cannot predict the potential impact of future HIPAA standards and other federal and state privacy and security laws that may be enacted at any time on our customers or on Omnicell. These laws could restrict the ability of our customers to obtain, use or disseminate patient information, which could reduce the demand for our products or force us to redesign our products in order to meet regulatory requirements.

We may need additional financing in the future to meet our capital needs and such financing may not be available on favorable terms, if at all, and may be dilutive to existing stockholders.*

We intend to continue to expend substantial funds for research and development activities, product development, expansion of sales and marketing activities and the potential acquisition and integration of complementary products and businesses. As a consequence, in the future we may need to seek additional financing to meet our working capital needs and to finance capital expenditures, as well as to fund operations or potential acquisitions. We may be unable to obtain any desired additional financing on terms favorable to us, if at all. If adequate funds are not available on acceptable terms, we may be unable to fund our expansion, successfully develop or enhance products, respond to competitive pressures or take advantage of acquisition opportunities, any of which could negatively affect our business. If we raise additional funds through the issuance of equity securities, our stockholders will experience dilution of their ownership interest. If we raise additional funds by issuing debt, we may be subject to limitations on our operations.

The lease term of our headquarters is up for renewal in mid-2009 and will be subject to market rates at that time.

Our headquarters and principal facilities are located in an area where rents have been increasing significantly. Upon renewal, we may be subjected to significantly higher lease rates than we pay now.

Our headquarters and principal facilities are located near known earthquake fault zones, and the occurrence of an earthquake or other natural disaster or any other catastrophic event could cause damage to our facilities and equipment, which could require us to cease or curtail operations.

Our headquarters and principal facilities are located near known earthquake fault zones and are vulnerable to significant damage from earthquakes. We are also vulnerable to damage from other types of disasters, including fires, floods, power loss, communications failures and similar events, including the effects of war or acts of terrorism. If any disaster were to occur, our ability to operate our business at our facilities could be seriously or completely impaired or destroyed. The insurance we maintain may not be adequate to cover our losses resulting from disasters or other business interruptions.

Anti-takeover provisions in our charter documents, our stockholders rights plan and under Delaware law may make an acquisition of us, which may be beneficial to our stockholders, more difficult.

We are incorporated in Delaware. Certain anti-takeover provisions of Delaware law and our charter documents as currently in effect may make a change in control of our company more difficult, even if a change in control would be beneficial to the stockholders. Our anti-takeover provisions include provisions in our certificate of incorporation providing that stockholders meetings may only be called by the board of directors and provisions in our bylaws providing that the stockholders may not take action by written consent and requiring that stockholders that desire to nominate any person for election to the board of directors or to make any proposal with respect to business to be conducted at a meeting of our stockholders be submitted in appropriate form to our Secretary within a specified period of time in advance of any such meeting. Delaware law also prohibits corporations from engaging in a business combination with any holders of 15% or more of their capital stock until the holder has held the stock for three years unless, among other possibilities, the board of directors approves the transaction. Our board of directors may use these provisions to prevent changes in the management and control of our company. Also, under applicable Delaware law, our board of directors may adopt additional anti-takeover measures in the future.

In February 2003, our board of directors adopted a stockholder rights plan that may have the effect of discouraging, delaying or preventing a change in control of our company that is beneficial to our stockholders. Pursuant to the terms of the plan, when a person or group, except under certain circumstances, acquires 15% or more of our outstanding common stock (other than two current stockholders and their affiliated entities, which will not trigger the rights plan unless they acquire beneficial ownership of 17.5% and 22.5% or more, respectively, of our outstanding common stock) or ten business days after commencement or announcement of a tender or exchange offer for 15% or more of our outstanding common stock, the rights (except those rights held by the person or group who has acquired or announced an offer to acquire 15% or more of our outstanding common stock) would generally become exercisable for shares of our common stock at a discount. Because the potential acquiror's rights would not become exercisable for our shares of common stock at a discount, the potential acquiror would suffer substantial dilution and may lose its ability to acquire us. In addition, the existence of the plan itself may deter a potential acquiror from acquiring us. As a result, either by operation of the plan or by its potential deterrent effect, a change in control of our company that our stockholders may consider in their best interests may not occur.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

Item 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Exhibit No.	Exhibit Title
3.1(1)	Amended and Restated Certificate of Incorporation of Omnicell, Inc.
3.2(2)	Certificate of Designation of Series A Junior Participating Preferred Stock.
3.3(3)	Bylaws of Omnicell, Inc., as amended.
4.1(1)	Form of Common Stock Certificate.
4.2	Reference is made to Exhibits 3.1, 3.2 and 3.3.
4.3(4)	Rights Agreement, dated February 6, 2003, between Omnicell, Inc. and EquiServe Trust Company, N.A.
31.1	Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.
31.2	Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.
32.1	Certifications required by Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended, and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350).

(1) Previously filed as an exhibit to the Registrant's Registration Statement on Form S-1 (File No. 333-57024), and amendments thereto, originally filed with the Securities and Exchange Commission on March 14, 2001, and incorporated herein by reference.

(2) Previously filed as an exhibit to the Registrant's Annual Report on Form 10-K (File No. 000-33043), and amendments thereto, originally filed with the Securities and Exchange Commission on March 28, 2003, and incorporated herein by reference.

(3) Previously filed as an exhibit to the Registrant's Quarterly Report on Form 10-Q (File No. 000-33043) filed with the Securities and Exchange Commission on August 9, 2007, and incorporated herein by reference.

(4) Previously filed as an exhibit to the Registrant's Current Report on Form 8-K (File No. 000-33043) filed with the Securities and Exchange Commission on February 14, 2003, and incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed in its behalf by the undersigned thereunto duly authorized.

OMNICELL, INC.

Date: November 9, 2007

/s/ ROBIN G. SEIM
Robin G. Seim
Vice President of Finance and Chief Financial Officer

INDEX TO EXHIBITS

Exhibit No.	Exhibit Title
3.1(1)	Amended and Restated Certificate of Incorporation of Omnicell, Inc.
3.2(2)	Certificate of Designation of Series A Junior Participating Preferred Stock.
3.3(3)	Bylaws of Omnicell, Inc., as amended.
4.1(1)	Form of Common Stock Certificate.
4.2	Reference is made to Exhibits 3.1, 3.2 and 3.3.
4.3(4)	Rights Agreement, dated February 6, 2003, between Omnicell, Inc. and EquiServe Trust Company, N.A.
31.1	Certification of Chief Executive Officer required by Rule 13a-14(a or Rule 15d-14(a of the Securities Exchange Act of 1934, as amended.)
31.2	Certification of Chief Financial Officer required by Rule 13a-14(a or Rule 15d-14(a of the Securities Exchange Act of 1934, as amended.)
32.1	Certifications required by Rule 13a-14(b or Rule 15d-14(b of the Securities Exchange Act of 1934, as amended, and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350.)

(1) Previously filed as an exhibit to the Registrant's Registration Statement on Form S-1 (File No. 333-57024), and amendments thereto, originally filed with the Securities and Exchange Commission on March 14, 2001, and incorporated herein by reference.

(2) Previously filed as an exhibit to the Registrant's Annual Report on Form 10-K (File No. 000-33043), and amendments thereto, originally filed with the Securities and Exchange Commission on March 28, 2003, and incorporated herein by reference.

(3) Previously filed as an exhibit to the Registrant's Quarterly Report on Form 10-Q (File No. 000-33043) filed with the Securities and Exchange Commission on August 9, 2007, and incorporated herein by reference.

(4) Previously filed as an exhibit to the Registrant's Current Report on Form 8-K (File No. 000-33043) filed with the Securities and Exchange Commission on February 14, 2003, and incorporated herein by reference.